Across TCGA pan-cancer cohorts, OR6N2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR6N2 data layer compared with 9 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OR6N2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR6N2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
UCEC, ESCA, and PRAD are the cancer types where OR6N2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.